Key results on urothelial carcinoma presented at ASCO GU 2021
Fredrik Liedberg and Thomas Powles discuss their thoughts on the game-changing results on metastatic urothelial carcinoma presented at ASCO GU. They cover updates on EV-301, JAVELIN Bladder 100, and their preferences on treatment sequencing. Also, they talk about the importance of CheckMate 274 in nonmetastatic patients, and discuss potential future approaches in this setting (15:35).
This activity is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.